Browse > Article

Smoking Status and Serum NSE Level, as Prognostic Factors in Adenocarcinoma of Lung  

Kim, Hee Kyoo (Department of Internal Medicine, College of Medicine, Kosin University College of Medicine)
Ok, Chul Ho (Department of Internal Medicine, College of Medicine, Kosin University College of Medicine)
Jung, Mann Hong (Department of Internal Medicine, College of Medicine, Kosin University College of Medicine)
Jang, Tae Won (Department of Internal Medicine, College of Medicine, Kosin University College of Medicine)
Publication Information
Tuberculosis and Respiratory Diseases / v.58, no.6, 2005 , pp. 582-589 More about this Journal
Abstract
Background : The incidence of lung adenocarcinoma, which is more prevalent in women and nonsmokers, is increasing. The aim of this study was to determine the prognostic factors of an adenocarcinoma of the lung. Material and method : The clinical information of patients diagnosed with an adenocarcinoma of the lung at the Kosin University Gospel Hospital from January 1994 to July 2004 was reviewed retrospectively. The survival time of these patients was analyzed by the patient's age, gender, performance status, weight loss, smoking history, location of the primary tumor, clinical stage, serologic tumor markers, and treatment modality. Results : For all 422 patients with an adenocarcinoma of the lung, 247 (58.5%) were male, and their mean age was 59.8 years the. The majority of patients were smokers (58.3%), and the tumors were located in the periphery (59.7%). In the smokers, the tumor was located more in the central airway compared to the non-smokers (42.8% vs. 31.9%, p=0.12). The overall median survival time was 390 days (95% CI;304-436 days). Univariate survival analysis revealed that an older age (${\geq}65$ years old), male, weight loss, smoker, central type, advanced clinical stage, elevated serum carcinoembryonic antigen (CEA, >5 ng/ml) and neuron specific enolase (NSE, >15 ng/ml), and the supportive care only were significantly poor prognostic factors. The median survival time was shorter in the smokers than nonsmokers (289 days vs. 533 days, p<0.001). In addition, it was also shorter in the elevated NSE group than in the normal range group (207 days vs. 469 days, p<0.001). Multivariate analysis showed that age, clinical stage, serum NSE, smoking status, and treatment modality were independent predictors of survival (hazard ratios: 1.68, 1.94, 1.92, 2.39 and 1.57, respectively). Conclusions : Smoking is an important prognostic factor in an adenocarcinoma of the lung, but not gender. This suggests that the better prognosis of women is more related with the lower rate of smoking. In addition, the elevated serum NSE is also an important prognostic in an adenocarcinoma of the lung.
Keywords
Adenocarcinoma of lung; survival time; smoking; serum NSE;
Citations & Related Records

Times Cited By SCOPUS : 0
연도 인용수 순위
  • Reference
1 Sobue T, Suzuki T, Fujimoto I, Doi O, Tateishi R, Sato T. Prognostic factors for surgically treated lung adenocarcinoma patients, with special reference to smoking habits. Jpn J Cancer Res 1991;82:33-9   DOI
2 Burghuber OC, Worofka B, Schernthaner G, Veter N, Neumann M, Dudczak R, et al. Serum neuronspecific enolase is useful marker for small cell lung cancer. Cancer 1990;65:1386-90   DOI   PUBMED   ScienceOn
3 Ferrigno D, Buccheri G, Giordan C. Neuron-specific enolase is an effective tumour marker in non-small cell lung cancer (NSCLC). Lung Cancer 2003;41:311-20   DOI   ScienceOn
4 Ebert W, Muley T, Drings P. Dose the assessment of serum markers in patients with lung cancer aid in the clinical decision making process? Anticancer Res 1996;16:2161-8
5 Foa P, Fornier M, Miceli R, Seregni E, Santambrogio L, Nosotti M, et al. Tumor markers CEA, NSE, SCC, TPA and Cypra 21.1 in resectable non-small cell lung cancer. Anticancer Res 1999;19:3613-8
6 Pujol JL, Simony J. Laurent JC, Richer G, Mary H, Bousquet J, et al. Phenotypic heterogeneity studied by immunohistochemistry and aneuploidy in non-small cell lung cancers. Cancer Res 1989;49:2797-802
7 Jang TW, Jung MH. Diagnostic usefulness of simultaneous measurement of serum tumor markers in lung cancer patients. Tuberc Respir Dis 1995;42:322-31   DOI
8 Maeda T, Ueoka H, Tabata M, Kiura K, Shiayama T, Gemba K, et al. Prognostic factors in advanced non-small cell lung cancer: elevated serum levels of neuron specific enolase indicated poor prognosis. Jpn J Clin Oncol 2000;30:534-41   DOI   ScienceOn
9 Andoh M, Gemma A, Takenaka K, Hisakatsu S, Yamada K, Usuki J, et al. Serum neuron specific enolase level as a prognostic factor in non-small cell lung cancer. Intern Med 1994;33:271-6   DOI   ScienceOn
10 Goodman MT, Kolonel LN, Wilkens LR, Yoshizawa CN, Marchand L. Smoking history and survival among lung cancer patients. Cancer Causes Control 1990;1:155-63   DOI   ScienceOn
11 Kosaka T, Yatabe Y, Endoh H, Kuwano H, Takahashi T, Mitsudomi T. Mutation of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications. Cancer Res 2004;64:8919-23   DOI   ScienceOn
12 Mountain CF. Revisions in the international system for staging lung cancer. Chest 1997;111:1710-7   DOI   PUBMED   ScienceOn
13 Hirsch FR, Skov BG. Neuroendocrine characteristics in bronchogenic adenocarcinoma and its clinical relevance. Lung Cancer 1993;10:209   DOI   ScienceOn
14 Nordquist LT, Simon GR, Cantor A, Alberts WM, Bepler G. Improved survival in never-smokers vs current smokers with primary adenocarcinoma of the lung. Chest 2004;126:347-51   DOI   ScienceOn
15 Mazzone PJ, Mekhail T, Arroliga AC. Is lung cancer in nonsmoker a different disease? Chest 2004;126:326-9   DOI   ScienceOn
16 Sanchez-Cespedes M, Ahrendt SA, Piantadosi S, Rosell R, Monzo M, Wu L, et al. Chromosomal alterations in lung adenocarcinoma from smokers and nonsmokers. Cancer Res 2001;61:1309-13
17 Powell CA, Spira A, Derti A, De Lisi C, LiuG, Borczuk A, et al. Gene expression in lung adenocarcinoma of smokers and nonsmokers. Am J Respir Cell Mol Biol 2003;29:157-62   DOI   ScienceOn
18 Kim JS, Park JY, Chae SC, Shin MC, Bae MS, Son JW, et al. Changing trends of clinical aspects in lung cancer from 1988 to 1996. J Korean Cancer Assoc 1999;31:112-9
19 Osann KE, Anton-Culver H, Kurosaki T, Taylor T. Sex differences in lung-cancer risk associated with cigarette smoking. Int J Cancer 1993;54:44-8   DOI   ScienceOn
20 Brownson RC, Loy TS, Ingram E, Myers JL, Alavanja MC, Sharp DJ, et al. Lung cancer in nonsmoking women. Cancer 1995;75:29-33   DOI   PUBMED   ScienceOn
21 Shimayama T, Ohnoshi T, Ueoka H, Horiguchi T, Kodani T, Segawa Y, et al. Serum neuron enolase (NSE) levels in patients with non small cell lung cancer. Nippon Kyobu Shikkan Gakkai Zasshi 1992;30:1097-102
22 Tammemagi CM, Neslund-Dudas C, Simoff M, Kvale P. Smoking and lung cancer survival. Chest 2004;125:27-37   DOI   ScienceOn
23 Barbone F, Bovenzi M, Cavallieri F, Stanta G. Cigarette smoking and histologic type of lung cancer in men. Chest 1997;112:1474-9   DOI   ScienceOn
24 Pujol JL, Boher JM, Grenier J, Quantin X. Cyfra 21-1, neuron specific enolase and prognosis of non-small cell lung cancer: prospective study in 621 patient. Lung Cancer 2001;31:221-31   DOI   PUBMED   ScienceOn
25 de Perrot M, Licker M, Bouchardy C, Usel M, Robert J, Spiliopoulos A. Sex differences in presentation, management, and prognosis of patients with non-small cell lung carcinoma. J Thoracic Cadiovasc Surg 2000;119:21-6   DOI   ScienceOn
26 Yesner R, Carter D. Pathology of carcinoma of the lung: changing patterns. Clin Chest Med 1982;3:257-89
27 Alberg AJ, Samet JM. Epidemiology of lung cancer. Chest 2003;123:21S-49S   DOI   ScienceOn
28 Brundage MD, Davies D, Mackillop WJ. Prognostic factors in non-small cell lung cancer. Chest 2002;122:1037-57   DOI   ScienceOn